

Table E-19. Racial makeup for trials comparing hormone with placebo

Study	White (%)	Black (%)	Hispanic (%)	Asian (%)	Other (%)	Not Classified (%)
Martin 1971						
Campbell 1977						
Baumgardner 1978						
Coope 1981						
Jensen 1983						
Foidart 1991						
Eriksen 1992						
Wiklund 1993						
Derman 1995						
Saletu 1995						
Good 1996	87.5	10.3			2.2	
Speroff (Study 1) 1996						
Chung 1996						
Speroff (Study 2) 1996						
Speroff (Study 3) 1996						
Bacchi-Modena 1997						
Baerug 1998						
Bech 1998						
de Vrijer 1999						
Leonetti 1999	45.1					54.9
Studd 1999	100					
Polo-Kantola 1999						

Study	White (%)	Black (%)	Hispanic (%)	Asian (%)	Other (%)	Not Classified (%)
Casper 1999						
Cohen 1999	83.5	13			3.5	
Rebar 2000						
Speroff (Study 1) 2000						
Rovati 2000						
Notelovitz 2000	82.6	8.3		2	6.7	0.4
Strickler 2000						
Notelovitz 2000						
DeAloysio 2000						
von Holst 2000						
Notelovitz 2000	87.7	4.3			8	
Alexandersen 2000						
Speroff (Study 2) 2000						
Rigano 2001						
Utian (CEE alone arms) 2001						
Simon 2001	68.6	27.4		0.8	3.2	
Soares 2001						
Utian (CEE/MPA arms) 2001						
Rozenbaum 2002	100					
Shulman (Study 1) 2002	80.6	13.3	4.4	0.7	1	
von Holst 2002						
Archer 2003	81.4	15.9		1.8	0.9	
Vestergaard 2003						
Speroff 2003	77.3	12	9	0.6	0.9	0.2
Jirapinyo 2003						
Haines 2003				100		
Hays 2003	83.9	6.8	5.3	2.2	1.8	
Gambacciani 2003						
Gelfand 2003	96.6	0.8		1.7	0.9	
Wren 2003						

Study	White (%)	Black (%)	Hispanic (%)	Asian (%)	Other (%)	Not Classified (%)
Simunic 2003						
Parsons 2003	88.2	6.4	3.2	1.1	1.1	
Berlex (SIP) 2003						
Rudolph 2004						
Yang 2004						
Schurmann 2004	100					
Utian 2004	81.2	17.4			1.4	
Dessole 2004	98.5					1.5
Duramed (SIP) 2004						
Brunner 2005	75.3	15.1	6.1	1.5	2	
Onalan 2005						
Bayer Healthcare (SIP) 2005						
Novartis (SIP) 2005						
Speroff (Study 1) 2006	78.1	8.7	12.5		0.7	
Simon 2006	75.5	19.5			5	
Nielsen 2006						
Osmanagaoglu 2006						
Speroff (Study 2) 2006	80.1	13.6	4.5		1.8	
Bachmann (d) 2007						
Maki 2007	81.7	9.5	6.1	1.1		1.6
Endrikat 2007						
Lee 2007				100		
Panay 2007	95	0.3		1	0.7	3
Simon 2007	84.5	9.7			5.8	
Pefanco 2007						
Bayer Healthcare (SIP) 2007						
Buster (Study 1) 2008	64.9	29.8	2.7	0.6	1.3	0.7
Veerus 2008						
Davis 2008	88.8	7.6	1.8	0.5	1.2	0.1
Bachmann 2008	92.2				7.8	

Study	White (%)	Black (%)	Hispanic (%)	Asian (%)	Other (%)	Not Classified (%)
Welton 2008						
Buster (Study 2) 2008	74	22	2		2	
Buster (Study 3) 2008	71.2	21.6	4.6		2.6	
Simon (SIP) 2008	81.8	3.6	10.5	2.4	1.6	0.1
Benster 2009						
Utian 2009	80.5	10.7	5.7	1.2	1.9	
Lobo 2009	80.7	13.8	3.2		1.8	0.5
Haines 2009						
Bachmann (d) 2009						
Hedrick 2009	86.1	10.2		1.5	2.2	
Baksu 2009						
Bachmann (Study 1) 2009	91.6					8.4
Freedman 2009	86.6	5.5	6.5	0.7	0.7	
Gast 2009						
Bachmann (Study 2) 2009	92.8					7.2
Hassa 2010						
Stevenson 2010						
Bachmann 2010	91.5	3.5			5	
Raghunandan 2010						
Hedrick 2010						
Liu 2011						
Lin 2011						
Demetrio 2011	79.9	6.3		3.1	10.7	
Liu 2012	66.9	14.6	16.6	0.6	1.3	
Archer 2012	80.6	17.7			1.7	
Archer 2012	80.6	17.7			1.7	
Cano 2012	100					
Polisseni 2013	59				41	
Raz 2013						
Archer 2013	67.6	24.2	7	0.6	0.6	

Study	White (%)	Black (%)	Hispanic (%)	Asian (%)	Other (%)	Not Classified (%)
Pinkerton 2013	87.8	10.7			1.5	

(a): data came from a conference abstract; (c): data came from posted results on the clinical trial registry; CEE: conjugated equine estrogen; (d): duplicate patient population with other included article; F/U: followup; (m): trial contains data from multiple publications; (SIP): data came from a package insert